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Abstract
Objective: We conducted a single-centre, randomised,
double-blinded, placebo-controlled phase II clinical
study to test safety and efficacy of a 12-week therapy
with low-dose (700 mg/daily) or high-dose (2800
mg/daily) of NAC.
Methods: Twenty-one patients (∆F508 homo/hetero-
zygous, FEV1 > 40% pred.) were included in the
study. After a 3-weeks placebo run-in phase, 11 pa-
tients received low-dose NAC, and 10 patients re-
ceived high-dose NAC. Outcomes included safety and
clinical parameters, inflammatory (total leukocyte
numbers, cell differentials, TNF-ʱ, IL-8) measures in
induced sputum, and concentrations of extracellular
glutathione in induced sputum and blood.
Results: High-dose NAC was a well-tolerated and safe
medication. High-dose NAC did not alter clinical or
inflammatory parameters. However, extracellular glu-
tathione in induced sputum tended to increase on
high-dose NAC.
Conclusions: High-dose NAC is a well-tolerated and
safe medication for a prolonged therapy of patients
with CF with a potential to increase extracellular glu-
tathione in CF airways.
Key words: Cystic fibrosis, N-acetylcysteine, induced
sputum, glutathione, inflammation
INTRODUCTION
Cystic fibrosis (CF) lung disease is the main cause of
morbidity and mortality in patients with CF. Excessive
neutrophil-dominated inflammation in airways is one
of the hallmarks of CF lung disease. This uncon-
trolled inflammation is believed to lead to lung dam-
age and dysfunction. There is a clear need for new
anti-inflammatory medications in CF. The use of ex-
isting anti-inflammatory therapies, such as oral corti-
costeroids [1, 2] or high-dose ibuprofen [3, 4], is limit-
ed because of extensive adverse events [5] or concerns
thereof [6].
Antioxidant drugs, such as N-acetylcysteine (NAC),
have attracted attention recently as potential therapies
for CF. The rationale to employ e.g. NAC is based on
the premise that CF airways are overexposed to oxi-
dants derived from bacteria [7, 8] or activated neu-
trophils [9]. Overexposure to oxidants, i.e. oxidative
stress, is a known amplifier of inflammation. There-
fore, antioxidant drugs may be useful to control both
oxidative stress and excessive inflammation in CF air-
ways.
While the safety and clinical efficacy of corticos-
teroids and high-dose ibuprofen have been thoroughly
tested in clinical studies, NAC has not been studied as
extensively. To date, only one short-term, open, un-
controlled, phase I study on NAC in CF has been pub-
lished [10]. These authors have tested NAC adminis-
tered for 4 weeks.
We have designed and conducted a single-centre,
randomised, double-blinded, placebo-controlled phase
II clinical study. We tested safety of a 12-week therapy
with low-dose (700 mg/daily) and high-dose (2800
mg/daily) of NAC, as well as its effects on clinical pa-
rameters, concentrations of extracellular glutathione in
induced sputum and blood, and inflammatory markers
in induced sputum of patients with CF.
METHODS
PATIENTS
The study was conducted between January 2000 and
September 2001 at the adult out-patient clinic of the
Hospital of Johann-Wolfgang-Goethe University,
Frankfurt/Main, Germany. Eligible patients were old-
er than 16 yrs and had an established diagnosis of CF
(repeatedly positive sweat tests, homo- or heterozy-
gous for ∆F508). Patients had stable disease within the
last four weeks before enrolment, and FEV1 > 40%
pred. Patients were not to be included if they had re-
cent (i.e. within the last four weeks) exacerbation of
CF lung disease, recent use of oral corticosteroids or
parenteral antibiotic therapy, history of haemoptysis,
known hypersensitivity to NAC or inactive ingredients
of the study medication (lactose, sodium cyclamate,
saccharin sodium, polyethylene glycol, sodium carbon-
ate, sodium bicarbonate, citric acid), history of severe
drug-related allergy, and clinically significant liver im-
pairment (AST/ GOT ≥ 50 IU/L). Informed con-
sents were obtained from all patients. The study pro-
tocol was approved by the local Human Ethics Board
and conducted according to GCP guidelines.
STUDY DESIGN AND MEDICATIONS
The study was conducted as a single-centre, ran-
domised, double-blind, placebo-controlled, parallel-
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placebo run-in phase. In total, patients came 5 times
to the study centre: visit 1 (screening / wash-out, day
1), visit 2 (randomisation / placebo run-in phase, day
22), visit 3 (begin of therapy with either 700 mg or
2800 mg NAC/daily, day 43), visit 4 (on study medica-
tion, day 64), and visit 5 (final visit, day 127). Patients’
allocation to either dose of NAC was done according
to a randomisation list (1 : 1 balanced) generated with
Random 1.0 software. Patients were instructed to
bring back empty medication containers which were
used to assess patients’ compliance. A patient was con-
sidered as compliant if she or he took at least 80% of
the dispensed medication.
SAFETY MEASURES AND ADVERSE EVENTS
Safety measures comprised adverse events, changes in
vital signs, and safety laboratory parameters. Adverse
events were registered during visits 2, 3, 4, and 5. Ex-
acerbations of CF lung disease were counted as ad-
verse events. Vital signs were registered during each
visit at the study centre. Safety laboratory comprised
analyses of serum (AST/ALT, ʳ-GT, C-reactive pro-
tein), blood, and urine parameters. These were ob-
tained on visit 1 and 5. In addition, an overall tolera-
bility was assessed by both investigator and patient at
visit 5.
EFFICACY MEASURES
The following parameters were quantified for the sub-
sequent efficacy evaluation: pulmonary functions tests,
antioxidant markers (extracellular glutathione in in-
duced sputum and blood), and inflammation markers
(total leukocyte counts and cell differentials, Tumour
Necrosis Factor (TNF)-ʱ, and Interleukin (IL) -8) in
induced sputum. In addition, changes in disease symp-
toms (clinical symptoms / Quality of Life Question-
naire) were also registered during each visit.
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Fig. 1. A. A CONSORT
study flow chart of pa-
tient enrolment, follow-
up and analysis. B. Study
design. Visit 3 (at the
end of placebo run-in
phase) was defined as
baseline for subsequent
analyses.
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MEASURES
Sputum samples were collected during visits 2, 3, 4
and 5. Sputum induction was performed according to
the standard protocols as described by us previously
[11]. Sputum samples were obtained, and small
aliquots were sent for microbiology analysis. The re-
mainders were processed as described in our previous
publication [11]. This protocol enabled measures of
both extracellular glutathione and cytokines in sputum
supernatants, as well as total leukocyte numbers and
cell differentials in the sputum’s solid phase. In brief,
induced sputum was mixed with ice-cold phosphate-
buffered saline, gently mixed and vortexed, and cen-
trifuged to separate supernatant (to analyse glu-
tathione and cytokines) and solid phase (to analyse
cells) [11]. We did not utilise dithiothreitol to obtain
sputum supernatants because this reagent affects glu-
tathione quantification in the sputum [12].
Extracellular glutathione was quantified by the stan-
dard methodology as described by us previously [11].
Cytokines (TNF-ʱ and IL-8) were quantified with
ELISA kits from R&D Systems.
The solid phase was solubilised with a mixture of
dithiothreitol and rhDNAse to obtain cells [11].
BLOOD SAMPLES AND OUTCOME MEASURES
Blood samples were obtained during visits 2, 3, 4 and
5. Samples were collected in EDTA tubes and immedi-
ately processed for glutathione [13].
DATA ANALYSES
Data are presented as median (25 -75%) throughout
the text and as box-whisker (min value, 25%, median,
75%, and max value) plots in the figures.
Safety and efficacy measures on treatment with either
dose of NAC (visits 4 and 5) were compared to the base-
line which was defined as the end of placebo run-in, i.e.
visit 3. Categorical data were analysed using Fishers ex-
act test. Ordinal or interval data were analysed using
Mann-Whitney (between-group comparisons), Wilcox-
on or Friedman tests (within-group comparisons),
where appropriate. Two-tailed p values were used, and
statistical significance was defined at p < 0.05.
ROLE OF FUNDING SOURCE
The sponsor of this study (Hexal AG) participated in
the study planning and study performance, but played
no role in data collection, data analysis, data interpre-
tation, or summarising the study results and writing
this manuscript.
RESULTS
SUBJECTS
A total of twenty-four patients were screened and
asked to participate in the study. Twenty-one patients
met the inclusion criteria and were included in the in-
tention-to-treat analysis (Table 1). Eleven patients
were randomly assigned to receive 700 mg/daily of
NAC (low-dose; Table 1), and ten patients were ran-
domly assigned to receive 2800 mg/daily of NAC
(high-dose; Table 1). Patients in both groups were
comparable in demographic and clinical parameters
(Table 1). For instance, both groups were not signifi-
cantly different in the degree of airway obstruction at
visit 1: median (25-75%) FEV1 of 80.60 (55.30-
90.00)% pred. in the 700 mg/daily NAC vs. 65.80
(62.90-73.40)% pred. in the 2800 mg/daily NAC
(Table 1 and Fig. 2, visit 1; p = 0.43).
COMPLIANCE
The compliance was found to be good, with the calcu-
lated compliance rates of > 80 per cent for both study
groups.
SAFETY
Both study groups exhibited comparable numbers of
mild-to-moderate adverse effects (24 on 700 mg/daily
of NAC, and 24 on 2800 mg/daily of NAC; p > 0.5).
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Table 1. Patient characteristics.
700 mg NAC 2800 mg NAC
Number of patients 11 10
Male/female (n) 9/2 7/3
Age 27.0 (21.0 – 35.0) 28.5 (24.0 – 35.0)
Height (cm) 168.0 (163.0 – 178.0) 174.0 (168.0 – 178.0)
Weight (kg) 65.5 (59.0 – 70.40) 64.5 (57.4 – 72.0)
Pseudomonas aeruginosa 43
Staphylococcus aureus 11
Various bacteria / saprophytic flora 66
FEV1 (% pred) 80.6 (55.3 – 90.0) 65.8 (62.9 – 73.4)
FVC (% pred) 82.6 (78.4 – 100.4) 84.8 (79.6 – 91.2)
MEF25-75 (% pred) 41.1 (12.4 – 68.1) 21.6 (19.6 – 27.9)
Data are shown as median (25 – 75%) values
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CF lung disease.
There have been three adverse effects which were
rated as “serious”. Two adverse effects (polypectomia:
the 700 mg/daily NAC group; haemoptysis during a
common cold: the 2800 mg NAC/daily group) were
rated as non-related to the study medication. With one
adverse effect, the causal relationship between the
study drug and adverse event was rated as “possible”.
This adverse event was in one patient in the 700
mg/daily NAC study group who developed gastroin-
testinal bleeding.
Twenty patients (both groups combined, one report
missing) reported the study medication as a “very
good” or “good” tolerable.
EFFICACY MEASURES
1. Pulmonary function tests
Both study groups demonstrated comparable baseline
values of FEV1 before the start of NAC therapy (Fig.
2, visit 3; p = 0.65). FEV1 did not change significantly
during medication with either doses of NAC (Fig. 2; p
> 0.3 for both groups).
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Fig. 2. Box and whisker
plots for FEV1 (% pre-
dicted) at each of the
five study visits. Whis-
kers represent minimum
and maximum values,
box represents 25 and
75 percentiles, • repre-
sents median values.
Visit 3 at the end of
placebo run-in phase de-
fines the baseline.
Fig. 3. A. Box and
whisker plots for extra-
cellular glutathione in in-
duced sputum at the
four study visits when
induced sputum samples
were collected. Whiskers
represent minimum and
maximum values, box
represents 25 and 75
percentiles, • represents
median values. Visit 3 at
the end of placebo run-
in phase defines the
baseline. B. Box and
whisker plots for extra-
cellular glutathione in
blood plasma at the four
study visits when blood
samples were collected.
Whiskers represent min-
imum and maximum
values, box represents
25 and 75 percentiles,
• represents median val-
ues. Visit 3 at the end of
placebo run-in phase de-
fines the baseline.
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and blood plasma
Both study groups demonstrated comparable concen-
trations of extracellular total glutathione in induced
sputum at the baseline (i.e. visit 3): 21.2 (7.2 – 34.02)
ﾵM in the 700 mg/daily NAC vs. 18.6 (2.8 – 32.4) ﾵM
in the 2800 mg/daily NAC (Fig. 3A, visit 3; p = 0.71).
In the 700 mg/daily NAC, the median sputum con-
centrations of total glutathione tended to decrease
during therapy with NAC, compared to the baseline,
i.e. visit 3: 23.2 (7.2 – 34.0) ﾵM vs. 14.0 (2.3 – 24.8) at
visit 4 and 16.4 (3.0 – 31.5) ﾵM at visit 5 (Fig. 3A).
However, these differences did not reach statistical
significance (p > 0.3).
On the contrary, in the 2800 mg/daily NAC, the
median values of total glutathione in induced sputum
tended to increase on NAC compared to the baseline
(visit 3): 18.6 (2.8 – 32.14) ﾵM vs. 27.2 (11.2 – 33.0)
ﾵM at visit 4 and 31.3 (0.2 – 44.3) ﾵM at visit 5 (Fig.
3A). Similar to the 700 mg/daily NAC group, these
differences did not reach statistical significance (Fig.
3A, visits 3 – 5; p > 0.8).
This study confirmed our previous report [11] that
total glutathione in sputum samples of patients with
CF is in reduced form (> 81%; data not shown).
With regard to extracellular total glutathione in
blood plasma, both study groups demonstrated com-
parable concentrations of this antioxidant at the base-
line (i.e. visit 3): 1.0 (0.9 – 1.3) ﾵM in the 700 mg/daily
NAC vs. 1.4 (1.0 – 1.9) ﾵM in the 2800 mg/daily NAC
(Fig. 3B, visit 3; p = 0.37). In both study groups, there
were no significant changes in concentrations of total
glutathione in blood plasma during treatment with
NAC (Fig. 3B, visits 3 – 5; p > 0.3 for both groups).
3. Inflammatory Markers in Induced Sputum
Both groups were not significantly different in total
number of leukocytes in induced sputum at the base-
line (visit 3): 56.6 (32.0 – 122.5) x 106 leukocytes in the
700 mg/daily NAC vs. 31.5 (20.0 – 113.7) x 106 leuko-
cytes in the 2800 mg/daily NAC (p = 0.51). In the 700
mg/daily NAC, total number of leukocytes did not
change significantly during active therapy (visits 4 and
5: 102 (55.2 – 164.0) x 106 and 56.0 (36.0 – 235.0) x
106 leukocytes, respectively; p > 0.3). The same was
true for the 2800 mg/daily NAC study group (visits 4
and 5: 48.6 (42.6 – 186.2) x 106 and 36.8 (19.9 – 110.8)
x 106; respectively; p > 0.3).
In both study groups, sputum leukocytes were pre-
dominantly neutrophils (data not shown).
Sputum TNF-ʱ. Patients in the 700 mg/daily NAC
demonstrated slightly lower concentrations of sputum
TNF-ʱ at the baseline (visit 3): 68.4 (30.0 – 140.0)
pg/mL vs. 140.0 (105.0 – 541.5) pg/mL; Fig. 4A; p =
0.17). Further, in both groups TNF-ʱ exhibited simi-
lar kinetics during therapy with NAC: it raised slightly
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Fig. 4. A. Box and
whisker plots for TNF-
ʱ in induced sputum at
the four study visits
when induced sputum
samples were collected.
Whiskers represent min-
imum and maximum
values, box represents
25 and 75 percentiles,
• represents median val-
ues. Visit 3 at the end of
placebo run-in phase
defines the baseline. B.
Box and whisker plots
for IL-8 in induced spu-
tum at the four study
visits when induced
sputum samples were
collected. Whiskers re-
present minimum and
maximum values, box
represents 25 and 75
percentiles, • represents
median values. Visit 3 at
the end of placebo run-
in phase defines the
baseline.
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these variations did not reach statistical significance in
either study group (Fig. 4A; p > 0.6 for both groups).
Sputum IL-8. Patients from both study groups
demonstrated comparable concentrations of sputum
IL-8. In specific, patients in the 700 mg/daily NAC
study group had 68.6 (30.0 – 136.1) pg/mL, whereas
patients in the 2800 mg/daily NAC study group
demonstrated 90.2 (47.4 – 131.2) pg/mL (Fig. 4B, visit
3; p = 0.5). In contrast to TNF-ʱ, concentrations of
IL-8 in induced sputum demonstrated less variations
in both study groups during therapy with NAC (Fig.
4B; p > 0.1 for both groups).
DISCUSSION
High-dose oral NAC is a promising new drug to sup-
press oxidative stress and excessive inflammation in
CF airways. We conducted a single-centre, randomised,
double-blinded, placebo-controlled phase II study on
safety and efficacy of a prolonged (12-weeks) therapy
with low- (700 mg/daily) or high-dose (2800
mg/daily) NAC in patients with CF.
Until recently, there was only one report from a
phase I study by Tirouvanziam et al [10] on high-dose
NAC for therapy of CF . We were unaware of their
study when the present study was designed and con-
ducted. Both our and the study Tirouvanziam et al [10]
utilised some similar measures, as well as some differ-
ent ones. Therefore, both studies provide confirmato-
ry as well as non-redundant information about safety
and efficacy of high-dose NAC in patients with CF.
The first important observation similar between our
and the study by Tirouvanziam et al [10] is that high-
dose NAC is a safe medication for therapy of CF. In
our study, 2800 mg/daily NAC was well tolerated over
the course of 12 weeks. Further, neither study re-
vealed any specific risks associated with high-dose
NAC in patients with CF.
Second, neither study observed any changes in pul-
monary function on high-dose NAC. Yet, it is proba-
bly premature to rule out any beneficial effects of
high-dose NAC. The timeframes of both studies
could have been too short for this outcome measure
to show significant changes. The timeframe of our
study (12 weeks) was longer, however, it may take
months to detect these changes. Indeed, the studies on
e.g. high-dose ibuprofen, another anti-inflammatory
drug for therapy of CF, went on for 4 or 2 years [3, 4]
to register a significant impact of the anti-inflammato-
ry drug.
Both studies on high-dose NAC quantified glu-
tathione, important antioxidant in CF, which is expect-
ed to be augmented by NAC supplementation. With
respect to glutathione, both studies deliver non-redun-
dant information.
Our study focused on extracellular glutathione in
induced sputum and blood plasma. Induced sputum
samples airway secretions in a non-invasive way, and
our research group was the first one to adapt the pro-
tocol of induced sputum processing to quantify extra-
cellular glutathione [12], also in patients with CF [11].
The rationale to measure extracellular glutathione
comes from the fact that this antioxidant might be in
deficiency in CF airways [13]. This deficiency is a direct
consequence of the malfunctioning glutathione-export-
ing function of CF transmembrane conductance regu-
lator (CFTR) protein [14-16]. Decrease in extracellular
glutathione is thought to aggravate oxidative stress and
promote inflammation in CF airways [17, 18]. There-
fore, therapeutic interventions capable of increasing
extracellular glutathione in CF airways are expected to
bring about beneficial clinical effects. Our study
demonstrated that high-dose NAC tended to increase
concentrations of extracellular glutathione in induced
sputum. Further, these trends appeared to be specific
to the airways, as no such trends were seen with regard
to extracellular glutathione in blood plasma.
By contrast, Tirouvanziam et al [10] focused on
studying intracellular glutathione in blood neutrophils
and whole blood lysates (predominantly, red blood
cells). These authors observed significant changes in
intracellular glutathione in neutrophils and in whole
blood lysates. It is plausible that blood cells (including
neutrophils) increase their intracellular glutathione
concentrations on high-dose NAC. Blood cells are
likely to be exposed to the much higher concentrations
of NAC than the cells in the lung.
The increase of intracellular glutathione in neu-
trophils could explain the trends towards increased ex-
tracellular glutathione in induced sputum samples. Pre-
viously, we reported high concentrations of reduced
glutathione in sputum samples from patients with CF
[11], and the present study confirmed our previous
observation. Given the impairment of glutathione-ex-
porting function of mutated CFTR in CF airway ep-
ithelium [14-16], high concentrations of reduced glu-
tathione can be explained by its efflux from apoptotic
cells, such as neutrophils. Such efflux of reduced glu-
tathione has been shown with respect to many cell
types undergoing apoptosis [19-21]. This efflux in-
volves multidrug resistance-associated protein (MRP)-
1 [22, 23], i.e. is CFTR-independent. One could specu-
late that high-dose NAC provides peripheral neu-
trophils with higher intracellular glutathione, and that
these neutrophils are capable of releasing higher, than
normally, concentrations of glutathione in CF airways.
Both studies studied markers of airway inflamma-
tion in induced sputum (ours: TNF-ʱ and IL-8, Tirou-
vanziam et al: neutrophil elastase and IL-8). Both stud-
ies should be comparable because of similar method-
ologies to obtain sputum supernatant. Sputum super-
natants were extracted with phosphate-buffered saline,
i.e. without dithiothreitol. Dithiothreitol interferes
with quantification of glutathione in induced sputum
[12] and confounds cell functional outcomes [10].
In neither study were the induced sputum cytokines
affected by high-dose NAC. Specifically, the sputum
concentrations of TNF-ʱ in the present study were
not decreased by high-dose NAC. Further, the sputum
IL-8 concentrations also remained unaffected by
NAC. Supporting these data, not all patients in the
study by Tirouvanziam et al [10] responded to high-
dose NAC by decreasing sputum IL-8. By contrast, de-
creases in activity of neutrophil elastase after 4 weeks
on high-dose NAC were by far more prominent and
significant [10]. Neutrophil elastase is a neutrophil-
specific factor. Its suppression caused by high-dose
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NAC [10] may indicate that neutrophils are the prima-
ry target of this drug in patient with CF.
There were some differences between our study
and the study by Tirouvanziam et al [10]. For instance,
we did not observe any significant changes in total
leukocyte numbers in induced sputum, whereas they
reported decrease in these numbers on high-dose
NAC. These differences can be explained by the dif-
ferences in lengths between the two studies (12 weeks
vs. 4 weeks). The total leukocyte number is sputum
varies depending on the phase of CF lung disease (re-
mission vs. exacerbation). A prolonged 12-weeks study
is more likely to be affected by clinical exacerbations.
In conclusion, our study demonstrates that high-
dose NAC is a well-tolerated and safe medication for a
prolonged therapy of patients with CF with a poten-
tial capacity to increase extracellular glutathione in CF
airways. Long-term and larger studies are necessary to
confirm the antioxidant and anti-inflammatory activity
of high-dose NAC, and its implications on clinical dis-
ease in patients with CF.
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